Ontology highlight
ABSTRACT:
SUBMITTER: Dunavin NC
PROVIDER: S-EPMC3769940 | biostudies-literature | 2013 Aug
REPOSITORIES: biostudies-literature
Dunavin Neil C NC Wei Lai L Elder Patrick P Phillips Gary S GS Benson Don M DM Hofmeister Craig C CC Penza Sam S Greenfield Carli C Rose Karen S KS Rieser Gisele G Merritt Lisa L Ketcham Jill J Heerema Nyla N Byrd John C JC Devine Steven M SM Efebera Yvonne A YA
Leukemia & lymphoma 20121231 8
Autologous stem cell transplant (ASCT) is an effective treatment for multiple myeloma (MM). However, the timing of ASCT in the era of novel agents (lenalidomide, thalidomide, bortezomib) is unknown. We retrospectively reviewed the outcome of patients with MM who received novel agent-based induction treatment and received first ASCT within 12 months of diagnosis (early ASCT, n = 102) or at a later date (late ASCT, n = 65). Median time to ASCT was 7.9 months vs. 17.7 months in early vs. late ASCT. ...[more]